7 unknown, 6 completed, 1 not yet recruiting, 1 recruiting. 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Unknown 7, Completed 6, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow SHR-1210: new trials by email Literature Review of SHR-1210 trials Research Report on SHR-1210
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial Camrelizumab, Nab-paclitaxel, Cisplatin - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer | Phase 3 | Not yet recruiting | Xuekui Liu | 212 | 2027-01-01 | 2026-11-19 |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell Camrelizumab, Apatinib - Esophageal Cancer | Phase 3 | Unknown | Feng Wang | 234 | 2021-12-05 | 2021-09-20 |
| Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC Camrelizumab, Placebo, Cisplatin - Non-Small-Cell Lung Cancer | Phase 3 | Completed | Guangdong Association of Clinical Trials | 60 | 2021-05-28 | 2026-05-20 |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC camrelizumab, Apatinib Mesylate, Paclitaxel - Gastric Cancer | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 550 | 2020-09-21 | 2026-01-20 |
| Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Camrelizumab, Investigator's choice of Chemotherapy - Classical Hodgkin Lymphoma | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 56 | 2020-07-17 | 2021-02-08 |
| A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. Carelizumab, Nab-paclitaxel, Apatinib - Breast Cancer, Triple Negative Breast Cancer | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 80 | 2020-07-14 | 2023-05-06 |
| Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer Camrelizumab, Paclitaxel, Cisplatin - Esophageal Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 396 | 2020-06-30 | 2021-09-16 |
| A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC SHR-1210, Apatinib, Sorafenib - Locally Advanced or Metastatic and Unresectable HCC | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 543 | 2019-06-10 | 2024-02-06 |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. SHR-1210, FOLFOX4, Placebo - Advanced Hepatocellular Carcinoma | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 396 | 2019-05-31 | 2022-02-10 |
| A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy SHR-1210, Capecitabine, Oxaliplatin - Gastric Cancer, GastroEsophageal Cancer | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 885 | 2019-03-07 | 2025-09-16 |
| Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer SHR-1210, Placebo, paclitaxel - Advanced Esophageal Cancer | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 596 | 2018-12-03 | 2022-12-07 |
| Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma Camrelizumab, Placebos, Gemcitabine - Nasopharyngeal Carcinoma | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 263 | 2018-11-13 | 2022-07-01 |
| A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC SHR-1210, The placebo - Lung Cancer Squamous Cell, Lung Cancer Stage IV | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 390 | 2018-11-09 | 2021-03-15 |
| PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Camrelizumab - Nasopharyngeal Neoplasms | Phase 3 | Unknown | Sun Yat-sen University | 450 | 2018-07-02 | 2024-04-09 |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC SHR-1210, Carboplatin, Pemetrexed - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 419 | 2017-05-12 | 2020-06-09 |
| Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer camrelizumab, Docetaxel, Irinotecan - Esophageal Carcinoma | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 457 | 2017-05-05 | 2024-01-22 |
Esophageal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Stomach Neoplasms (2) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Nasopharyngeal Carcinoma (1) · Nasopharyngeal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (12) · Feng Wang (1) · Guangdong Association of Clinical Trials (1) · Sun Yat-sen University (1) · Xuekui Liu (1)
China (14) · Belgium (1) · Germany (1) · Hong Kong (1) · Italy (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · Ukraine (1) · United States (1)
Caicun Zhou, MD, PhD (1) · Feng Wang (1) · Jianjun Zou, MD, PhD (1) · Jianming Xu, Ph.D (1) · Jun Ma, MD (1) · Li Zhang, MD (1) · Qing Yang (1) · Qing Yang, MD (1) · Ruihua Xu (1) · Shukui Qin, MD (1) · Shukui Qing, MD (1) · Wei Shi, MD (1) · Wu Yi Long, PhD (1)
PMID 32416073, PMID 33347829, PMID 34174189, PMID 34519801, PMID 34923163, PMID 34980131, PMID 35936702, PMID 36194670, PMID 36331328, PMID 36646210, PMID 37139963, PMID 37409613, PMID 37499670, PMID 39438442, PMID 39608979, PMID 39929333, PMID 40079940, PMID 41308676, PMID 41609753, PMID 41791006, PMID 41819560